Longitudial Study of SPIDDM

JRCT ID: jRCTs051240223

Registered date:23/12/2024

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Slowly progressive insulin dependent (type 1) diabetes mellitus
• Date of first enrollment: 23/12/2024
• Target sample size: 20
• Study type: Interventional
• Intervention(s): PET imaging with the test drug 18F-labeled exendin-4.

Outcome(s)

• Primary Outcome: Pancreatic beta-cell mass
• Secondary Outcome: Insulin secretion capacity, blood glucose fluctuations

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: <= 90age old
• Gender: Both
• Include criteria: Patients diagnosed with slowly progressive type 1 diabetes mellitus (probable) or suspected to have slowly progressive type 1 diabetes mellitus with positive islet-related autoantibodies.

Exclude criteria

Severe hepatic or renal dysfunction (AST>200U/L, ALT>200U/L, or eGFR<15mL/min/1.73m2)
Use of GLP-1-related drugs that cannot be discontinued
Unsuitable or contraindicated for Exenatide administration
Alcohol, Tween 80, Metoclopramide and grucagon intolerance
Other conditions that, in the judgment of the principal investigator/associate investigator, render the subject unsuitable for participation in this study

Related Information

• Primary Sponsor: Murakami Takaaki